Table 4.
Top 20 vinorelbine-associated AEs with the strongest signal strength in FAERS.
| Top 20 AEs with the strongest signal strength | Frequency | ROR (95% CI) | IC (IC025) | |
|---|---|---|---|---|
| 1 | Epiploic appendagitis | 4 | 344.38 (126.60–936.78) | 8.37 (0.98) |
| 2 | Gastric volvulus | 3 | 206.16 (65.54–648.53) | 7.65 (0.51) |
| 3 | Erythropenia | 7 | 200.98 (94.91–425.57) | 7.61 (1.91) |
| 4 | Injection site phlebitis | 5 | 184.24 (94.91–425.57) | 7.49 (1.35) |
| 5 | Pseudocirrhosis | 3 | 93.28 (29.88–291.18) | 6.53 (0.50) |
| 6 | Neutropenic sepsis | 42 | 52.36 (38.62–70.99) | 5.69 (4.13) |
| 7 | Extravasation | 23 | 50.06 (33.20–75.48) | 5.63 (3.44) |
| 8 | Superior vena cava syndrome | 3 | 44.36 (14.26–138.01) | 5.46 (0.46) |
| 9 | Vascular pain | 5 | 40.10 (16.65–96.58) | 5.32 (1.23) |
| 10 | Lymphangiosis carcinomatosa | 4 | 34.37 (12.87–91.78) | 5.10 (0.87) |
| 11 | Febrile bone marrow aplasia | 15 | 34.22 (20.60–56.85) | 5.09 (2.75) |
| 12 | Metastases to adrenals | 3 | 30.21 (9.72–93.90) | 4.91 (0.42) |
| 13 | Ileus paralytic | 14 | 29.36 (17.37–49.66) | 4.87 (2.59) |
| 14 | Ejection fraction abnormal | 4 | 28.90 (10.82–77.16) | 4.85 (0.84) |
| 15 | Megacolon | 4 | 23.19 (8.69–61.88) | 4.85 (0.84) |
| 16 | PO2 decreased | 3 | 21.79 (7.01–67.67) | 4.53 (0.80) |
| 17 | Panniculitis | 6 | 21.53 (9.66–47.99) | 4.44 (0.37) |
| 18 | Pneumoperitoneum | 4 | 20.22 (7.58–53.96) | 4.42 (1.36) |
| 19 | Non-small cell lung cancer | 10 | 20.09 (10.80–37.38) | 4.32 (2.00) |
| 20 | Neutropenic colitis | 4 | 18.98 (7.11–50.63) | 4.24 (0.75) |